Dmitriev told Sputnik that clinical trials in Saudi Arabia, the United Arab Emirates (UAE), the Philippines, India and Brazil would begin this month.
Post-registration studies involving more than 40,000 people began in Russia on August 26, before AstraZeneca began its phase 3 trial in the United States with 30,000 participants. Clinical trials in Saudi Arabia, the United Arab Emirates (UAE), the Philippines and India and Brazil will begin this month. Preliminary effects of the Phase 3 trial will be published in October-November 2020,” Dmitriev said.
Russia in close discussion with the Indian government and India’s major drug brands regarding the production location of the Sputnik V vaccine in India.
On 11 August, the Sputnik V vaccine evolved jointly through RDIF and the Gamaleya National Centre for Epidemiology and Microbiology Research registered through the Russian Ministry of Health and has become the world’s first registered vaccine opposed to COVID-19.
According to Russian researchers, Sputnik V is a human adenoviral vector vaccine that fights coronavirus disease.
“India has been a very important spouse of Russia. India is one of the leading generating countries. Approximately 60% of all vaccines in the world are produced in India. We have a close conversation with the relevant ministries and the Indian government. the country’s leading manufacturer in terms of the production location of the Sputnik V vaccine in India. And we have concluded some agreements with major companies,” Dmitriev said in response to an AN consultation on discussions between India and the Russian government on Sputnik Vaccine.
“We recognize India and its prospect of being one of the supports for vaccine production not only in Indian markets but also in other countries. We greatly appreciate the well-balanced technique expressed through Indian partners from the beginning. They began to wonder how our vaccine works and we appreciate the fact that they have not withdrawn to attack our vaccine, but we do watch to perceive it. “The adenoviral vaccine platform is the maximum moderate technique.
On 4 September, a medical journal The Lancet published the effects of phase I-II clinical trials of the Russian vaccine demonstrating its protection and efficacy. “Sputnik V Phase I-II clinical trials showed no serious adverse occasions (3) for any of the criteria, while the occurrence of serious adverse occasions for other candidate vaccines oscillated between 1% and 25%,” says the DRIF press release.
In one hundred percent of clinical trial participants, Sputnik V generated a strong cellular and fun immune response. The antibody point neutralizes the virus of volunteers vaccinated with Sputnik V 1. 4 to 1. 5 times higher than the antibody grades of patients who had recovered from COVID-19. , “RDIF press release read below.
Click here to read that Mint ePapermint is now on Telegram. Join the mint channel on your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any of our emails, check your spam folder.